Belizatinib
Belizatinib (TSR-011) is a potent, orally bioavailable small molecule that dually inhibits ALK and the TRKA/B/C kinases. It demonstrates activity in cellular assays and has shown antitumor efficacy in preclinical in vivo models of ALK-driven cancers, supporting its use as a research tool in oncology.
Product Specifications
CAS Number
1357920-84-3
Product Name Alternative
Anaplastic lymphoma kinase (ALK), Anaplastic lymphoma kinase, ALK tyrosine kinase receptor, ALK, Belizatinib, Cluster of differentiation 246, CD246, inhibit, Inhibitor, TSR 011, TSR011, TSR-011, Tropomyosin related kinase receptor, Trk Receptor, Trk receptor, Trkreceptor
Field of Research
Cardiovascular Research, Signal Transduction
Purity
99.33% (May vary between batches)
Solubility
DMSO:60 mg/mL (103.85 mM)
Smiles
CC (C) NC (=O) [C@H]1CC[C@H] (CC1) n1c (NC (=O) c2ccc (F) cc2) nc2ccc (CN3CCC (CC3) C (C) (C) O) cc12
Molecular Formula
C33H44FN5O3
Molecular Weight
577.73
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-11874R-BF488 100 µL
LMCD1 Polyclonal Antibody, AbBy Fluor™ 488 Conjugated
Sign In for Pricing
View Details 
36729061 1.0 µg DNA
PIRC100 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 